These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 26616140)
1. Identification of Small-Molecule Inhibitors of the Antiapoptotic Protein Myeloid Cell Leukaemia-1 (Mcl-1). Beekman AM; O'Connell MA; Howell LA ChemMedChem; 2016 Apr; 11(8):840-4. PubMed ID: 26616140 [TBL] [Abstract][Full Text] [Related]
2. Small-molecule Mcl-1 inhibitors: Emerging anti-tumor agents. Wan Y; Dai N; Tang Z; Fang H Eur J Med Chem; 2018 Feb; 146():471-482. PubMed ID: 29407973 [TBL] [Abstract][Full Text] [Related]
3. Structural revision of the Mcl-1 inhibitor MIM1: synthesis and biological studies on ovarian cancer cells with evaluation of designed analogues. Paysant H; Hedir S; Justaud F; Weiswald LB; El Dine AN; Soulieman A; Hachem A; Elie N; Brotin E; Denoyelle C; Bignon J; Roussi F; Jouanne M; Tasseau O; Roisnel T; Voisin-Chiret AS; Grée R; Levoin N; Poulain L Org Biomol Chem; 2021 Oct; 19(41):8968-8987. PubMed ID: 34596646 [TBL] [Abstract][Full Text] [Related]
4. Small-Molecule and Peptide Inhibitors of the Pro-Survival Protein Mcl-1. Beekman AM; Howell LA ChemMedChem; 2016 Apr; 11(8):802-13. PubMed ID: 26696548 [TBL] [Abstract][Full Text] [Related]
5. Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors That Demonstrate in Vivo Activity in Mouse Xenograft Models of Human Cancer. Lee T; Christov PP; Shaw S; Tarr JC; Zhao B; Veerasamy N; Jeon KO; Mills JJ; Bian Z; Sensintaffar JL; Arnold AL; Fogarty SA; Perry E; Ramsey HE; Cook RS; Hollingshead M; Davis Millin M; Lee KM; Koss B; Budhraja A; Opferman JT; Kim K; Arteaga CL; Moore WJ; Olejniczak ET; Savona MR; Fesik SW J Med Chem; 2019 Apr; 62(8):3971-3988. PubMed ID: 30929420 [TBL] [Abstract][Full Text] [Related]
6. A competitive stapled peptide screen identifies a selective small molecule that overcomes MCL-1-dependent leukemia cell survival. Cohen NA; Stewart ML; Gavathiotis E; Tepper JL; Bruekner SR; Koss B; Opferman JT; Walensky LD Chem Biol; 2012 Sep; 19(9):1175-86. PubMed ID: 22999885 [TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of tyrosine derivatives as Mcl-1 inhibitors. Liu L; Liu R; Yang X; Hou X; Fang H Eur J Med Chem; 2020 Apr; 191():112142. PubMed ID: 32088497 [TBL] [Abstract][Full Text] [Related]
8. Drimane Derivatives as the First Examples of Covalent BH3 Mimetics that Target MCL-1. Daressy F; Malard F; Seguy L; Guérineau V; Apel C; Dumontet V; Robert A; Groo AC; Litaudon M; Bignon J; Desrat S; Malzert-Fréon A; Wiels J; Lescop E; Roussi F ChemMedChem; 2021 Jun; 16(11):1788-1797. PubMed ID: 33665938 [TBL] [Abstract][Full Text] [Related]
9. Structure-based design, synthesis, and evaluation of Bcl-2/Mcl-1 dual inhibitors. Zhu J; Wang Z; Guo Z; Zhang X; Song T; Guo Y; Ji T; Zhang Z Arch Pharm (Weinheim); 2020 May; 353(5):e2000005. PubMed ID: 32175625 [TBL] [Abstract][Full Text] [Related]
10. Discovery of Mcl-1 inhibitors from integrated high throughput and virtual screening. Mady ASA; Liao C; Bajwa N; Kump KJ; Abulwerdi FA; Lev KL; Miao L; Grigsby SM; Perdih A; Stuckey JA; Du Y; Fu H; Nikolovska-Coleska Z Sci Rep; 2018 Jul; 8(1):10210. PubMed ID: 29976942 [TBL] [Abstract][Full Text] [Related]
12. Interdiction at a protein-protein interface: MCL-1 inhibitors for oncology. Li K Bioorg Med Chem Lett; 2021 Jan; 32():127717. PubMed ID: 33253879 [TBL] [Abstract][Full Text] [Related]
13. Discovery of novel indazole-acylsulfonamide hybrids as selective Mcl-1 inhibitors. Wan Y; Li Y; Yan C; Wen J; Tang Z Bioorg Chem; 2020 Nov; 104():104217. PubMed ID: 32911192 [TBL] [Abstract][Full Text] [Related]
14. Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax). Leverson JD; Zhang H; Chen J; Tahir SK; Phillips DC; Xue J; Nimmer P; Jin S; Smith M; Xiao Y; Kovar P; Tanaka A; Bruncko M; Sheppard GS; Wang L; Gierke S; Kategaya L; Anderson DJ; Wong C; Eastham-Anderson J; Ludlam MJ; Sampath D; Fairbrother WJ; Wertz I; Rosenberg SH; Tse C; Elmore SW; Souers AJ Cell Death Dis; 2015 Jan; 6(1):e1590. PubMed ID: 25590800 [TBL] [Abstract][Full Text] [Related]
15. Pyoluteorin derivatives induce Mcl-1 degradation and apoptosis in hematological cancer cells. Doi K; Gowda K; Liu Q; Lin JM; Sung SS; Dower C; Claxton D; Loughran TP; Amin S; Wang HG Cancer Biol Ther; 2014; 15(12):1688-99. PubMed ID: 25535900 [TBL] [Abstract][Full Text] [Related]
17. Structure-Based Optimization of 3-Phenyl- Li Y; Fan W; Gong Q; Tian J; Zhou M; Li Q; Uwituze LB; Zhang Z; Hong R; Wang R J Med Chem; 2021 Jul; 64(14):10260-10285. PubMed ID: 34228434 [TBL] [Abstract][Full Text] [Related]
18. Synthesis and structure-activity relationship of coumarins as potent Mcl-1 inhibitors for cancer treatment. Xia YL; Wang JJ; Li SY; Liu Y; Gonzalez FJ; Wang P; Ge GB Bioorg Med Chem; 2021 Jan; 29():115851. PubMed ID: 33218896 [TBL] [Abstract][Full Text] [Related]
19. 1-Phenyl-1H-indole derivatives as a new class of Bcl-2/Mcl-1 dual inhibitors: Design, synthesis, and preliminary biological evaluation. Xu G; Liu T; Zhou Y; Yang X; Fang H Bioorg Med Chem; 2017 Oct; 25(20):5548-5556. PubMed ID: 28866374 [TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, stereochemical determination, molecular docking study, in silico pre-ADMET prediction and anti-proliferative activities of indole-pyrimidine derivatives as Mcl-1 inhibitors. Lamie PF; Philoppes JN Bioorg Chem; 2021 Nov; 116():105335. PubMed ID: 34509795 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]